173 related articles for article (PubMed ID: 37573674)
1. Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma.
Mouabbi JA; Raghavendra AS; Bassett RL; Christgen M; Middleton L; Teshome M; Nasrazadani A; Hortobagyi G; Hassan A; Tripathy D; Layman RM
Eur J Cancer; 2023 Sep; 191():113250. PubMed ID: 37573674
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Coexisting Lobular Carcinoma In Situ With Invasive Lobular Carcinoma.
Harbhajanka A; Lamzabi I; Syed S; Jain R; Ghai R; Reddy VB; Bitterman P; Gattuso P
Appl Immunohistochem Mol Morphol; 2016; 24(10):738-743. PubMed ID: 26574630
[TBL] [Abstract][Full Text] [Related]
3. The Pathologic Finding of Combined Lobular Carcinoma
Jean-Louis CJ; Masdon J; Smith B; Battles O; Dale P
Am Surg; 2017 May; 83(5):482-485. PubMed ID: 28541858
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.
Shah V; Nowinski S; Levi D; Shinomiya I; Kebaier Ep Chaabouni N; Gillett C; Grigoriadis A; Graham TA; Roylance R; Simpson MA; Pinder SE; Sawyer EJ
Breast Cancer Res; 2017 Jan; 19(1):7. PubMed ID: 28095868
[TBL] [Abstract][Full Text] [Related]
5. Synchronous lobular carcinoma in situ and invasive lobular cancer: marker or precursor for invasive lobular carcinoma.
Wallace AS; Xiang D; Hockman L; Arya M; Jeffress J; Wang Z; Dale PS
Eur J Surg Oncol; 2014 Oct; 40(10):1245-9. PubMed ID: 24857380
[TBL] [Abstract][Full Text] [Related]
6. Genetic predisposition to in situ and invasive lobular carcinoma of the breast.
Sawyer E; Roylance R; Petridis C; Brook MN; Nowinski S; Papouli E; Fletcher O; Pinder S; Hanby A; Kohut K; Gorman P; Caneppele M; Peto J; Dos Santos Silva I; Johnson N; Swann R; Dwek M; Perkins KA; Gillett C; Houlston R; Ross G; De Ieso P; Southey MC; Hopper JL; Provenzano E; Apicella C; Wesseling J; Cornelissen S; Keeman R; Fasching PA; Jud SM; Ekici AB; Beckmann MW; Kerin MJ; Marme F; Schneeweiss A; Sohn C; Burwinkel B; Guénel P; Truong T; Laurent-Puig P; Kerbrat P; Bojesen SE; Nordestgaard BG; Nielsen SF; Flyger H; Milne RL; Perez JI; Menéndez P; Benitez J; Brenner H; Dieffenbach AK; Arndt V; Stegmaier C; Meindl A; Lichtner P; Schmutzler RK; Lochmann M; Brauch H; Fischer HP; Ko YD; ; Nevanlinna H; Muranen TA; Aittomäki K; Blomqvist C; Bogdanova NV; Dörk T; Lindblom A; Margolin S; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Chenevix-Trench G; ; Lambrechts D; Weltens C; Van Limbergen E; Hatse S; Chang-Claude J; Rudolph A; Seibold P; Flesch-Janys D; Radice P; Peterlongo P; Bonanni B; Volorio S; Giles GG; Severi G; Baglietto L; McLean CA; Haiman CA; Henderson BE; Schumacher F; Le Marchand L; Simard J; Goldberg MS; Labrèche F; Dumont M; Kristensen V; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Kauppila S; Andrulis IL; Knight JA; Glendon G; Mulligan AM; Devillee P; Tollenaar RA; Seynaeve CM; Kriege M; Figueroa J; Chanock SJ; Sherman ME; Hooning MJ; Hollestelle A; van den Ouweland AM; van Deurzen CH; Li J; Czene K; Humphreys K; Cox A; Cross SS; Reed MW; Shah M; Jakubowska A; Lubinski J; Jaworska-Bieniek K; Durda K; Swerdlow A; Ashworth A; Orr N; Schoemaker M; Couch FJ; Hallberg E; González-Neira A; Pita G; Alonso MR; Tessier DC; Vincent D; Bacot F; Bolla MK; Wang Q; Dennis J; Michailidou K; Dunning AM; Hall P; Easton D; Pharoah P; Schmidt MK; Tomlinson I; Garcia-Closas M
PLoS Genet; 2014 Apr; 10(4):e1004285. PubMed ID: 24743323
[TBL] [Abstract][Full Text] [Related]
7. [Lobular carcinoma in situ (LCIS): risk factor and precursor of invasive lobular breast cancer].
Aulmann S; Penzel R; Schirmacher P; Sinn HP
Verh Dtsch Ges Pathol; 2007; 91():208-13. PubMed ID: 18314616
[TBL] [Abstract][Full Text] [Related]
8. Loss of heterozygosity on chromosome 11q13 in lobular lesions of the breast using tissue microdissection and polymerase chain reaction.
Nayar R; Zhuang Z; Merino MJ; Silverberg SG
Hum Pathol; 1997 Mar; 28(3):277-82. PubMed ID: 9042790
[TBL] [Abstract][Full Text] [Related]
9. Cadherin-catenin complex dissociation in lobular neoplasia of the breast.
Morrogh M; Andrade VP; Giri D; Sakr RA; Paik W; Qin LX; Arroyo CD; Brogi E; Morrow M; King TA
Breast Cancer Res Treat; 2012 Apr; 132(2):641-52. PubMed ID: 22080244
[TBL] [Abstract][Full Text] [Related]
10. Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast.
Lien HC; Chen YL; Juang YL; Jeng YM
Breast Cancer Res Treat; 2015 Apr; 150(2):447-55. PubMed ID: 25773929
[TBL] [Abstract][Full Text] [Related]
11. Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation.
Sasson AR; Fowble B; Hanlon AL; Torosian MH; Freedman G; Boraas M; Sigurdson ER; Hoffman JP; Eisenberg BL; Patchefsky A
Cancer; 2001 May; 91(10):1862-9. PubMed ID: 11346867
[TBL] [Abstract][Full Text] [Related]
12. Pleomorphic and Florid Lobular Carcinoma In Situ Variants of the Breast: A Clinicopathologic Study of 85 Cases With and Without Invasive Carcinoma From a Single Academic Center.
Shamir ER; Chen YY; Chu T; Pekmezci M; Rabban JT; Krings G
Am J Surg Pathol; 2019 Mar; 43(3):399-408. PubMed ID: 30489319
[TBL] [Abstract][Full Text] [Related]
13. Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships.
Sakr RA; Schizas M; Carniello JV; Ng CK; Piscuoglio S; Giri D; Andrade VP; De Brot M; Lim RS; Towers R; Weigelt B; Reis-Filho JS; King TA
Mol Oncol; 2016 Feb; 10(2):360-70. PubMed ID: 26643573
[TBL] [Abstract][Full Text] [Related]
14. Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review.
De Brot M; Koslow Mautner S; Muhsen S; Andrade VP; Mamtani A; Murray M; Giri D; Sakr RA; Brogi E; King TA
Breast Cancer Res Treat; 2017 Sep; 165(2):411-420. PubMed ID: 28612228
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion.
Andrade VP; Morrogh M; Qin LX; Olvera N; Giri D; Muhsen S; Sakr RA; Schizas M; Ng CK; Arroyo CD; Brogi E; Viale A; Morrow M; Reis-Filho JS; King TA
Mol Oncol; 2015 Apr; 9(4):772-82. PubMed ID: 25601220
[TBL] [Abstract][Full Text] [Related]
16. Clonality of lobular carcinoma in situ (LCIS) and metachronous invasive breast cancer.
Aulmann S; Penzel R; Longerich T; Funke B; Schirmacher P; Sinn HP
Breast Cancer Res Treat; 2008 Feb; 107(3):331-5. PubMed ID: 17380381
[TBL] [Abstract][Full Text] [Related]
17. Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity.
Giricz O; Reynolds PA; Ramnauth A; Liu C; Wang T; Stead L; Childs G; Rohan T; Shapiro N; Fineberg S; Kenny PA; Loudig O
J Pathol; 2012 Jan; 226(1):108-19. PubMed ID: 21953071
[TBL] [Abstract][Full Text] [Related]
18. Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ.
Miller ME; Muhsen S; Zabor EC; Flynn J; Olcese C; Giri D; Van Zee KJ; Pilewskie M
Ann Surg Oncol; 2019 Dec; 26(13):4317-4325. PubMed ID: 31552614
[TBL] [Abstract][Full Text] [Related]
19. High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients.
Vincent-Salomon A; Hajage D; Rouquette A; Cédenot A; Gruel N; Alran S; Sastre-Garau X; Sigal-Zafrani B; Fourquet A; Kirova Y
Breast; 2012 Jun; 21(3):380-3. PubMed ID: 22531230
[TBL] [Abstract][Full Text] [Related]
20. Axillary lymph node status and invasive lobular breast cancer : Analysis of the Clinical Tumor Register of the AGO Austria.
Danzinger S; Pöckl K; Kronawetter G; Pfeifer C; Behrendt S; Gscheidlinger P; Harrasser L; Mühlböck H; Dirschlmayer W; Schauer C; Reitsamer R; Uher H; Schönau K; Delmarko I; Singer CF
Wien Klin Wochenschr; 2023 Sep; 135(17-18):463-471. PubMed ID: 37010596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]